Subject:
- Active Sustance: Upadacitinib
- Name: Rinvoq®
- Therapeutic area: Ulcerative colitis
- Pharmaceutical company: AbbVie Deutschland GmbH & Co. KG
Time table:
- Start: 01.09.2022
- Final decision by G-BA: 16.02.2023
Final decision:
- Patients, who have had an inadequate response, no longer respond to conventional therapy, or have an intolerance or contraindication: No additional benefit proved
- Patients, who have had an inadequate response, no longer respond, or are intolerant to a biologic (TNF-α antagonist or integrin inhibitor or interleukin inhibitor): No additional benefit proved